Our results demonstrate that SGLT2 inhibitors confer robust protective effects across both infectious (pneumonia, bronchitis) and non-infectious (COPD, respiratory failure) respiratory outcomes. Here, SLC5A2 is linked to susceptibility to pneumonia measurement.